

Clinical effects of overwintered-stressed *Chondrus Crispus* and non-overwintered-stressed *Chondrus crispus* dietary supplementations



Beniamino Palmieri¹, Maria Vadalà², Carmen Laurino³

¹Professor, Department of General Surgery and Surgical Specialities, University of Modena and Reggio Emilia. Largo del Pozzo 71, 41124 Modena (MO). Second Opinion Medical Network, Modena (MO), Italy, ^{2,3}Medical Doctor, Department of General Surgery and Surgical Specialities, University of Modena and Reggio Emilia. Largo del Pozzo 71, 41124 Modena (MO). Second Opinion Medical Network, Modena (MO), Italy

Submitted: 03-09-2018

Revised: 19-09-2018

Published: 01-11-2018

ABSTRACT

Background: *Chondrus crispus* is red seaweed widespread in the northern Atlantic coasts due to the high proteins, burden it is quite helpful supplement for some symptoms such as fatigue, asthenia, and weakness and for supporting skeletal muscles in sports athletes.

Aims and Objectives: This retrospective observational “not inferiority” study investigates and compares the clinical effects of overwintered-stressed *Chondrus Crispus* and non-overwintered-stressed *Chondrus crispus* dietary supplementations for the treatment of musculoskeletal and articular symptomatology related diseases. **Materials and Methods:** Eighty patients were retrospectively reviewed through the Second Opinion Medical Network. Patients were prescribed 3 capsules/day after the main meals for 3 weeks of overwintered-stressed *Chondrus Crispus* or non-overwintered stressed *Chondrus crispus* dietary supplementations. Quality of life (QOL) assessment was evaluated by the Short Form-36 (SF-36) health survey questionnaire before starting the treatment and after the third week. Benefits declared by patients were also reported after the treatment in addition to some subjective observations related to the symptomatology and to the health status. **Results:** Fifty patients were treated with overwintered-stressed *Chondrus Crispus* and 30 patients were treated with the non-overwintered-stressed *Chondrus crispus* dietary supplementation. The general benefit of treatment with overwintered-stressed *Chondrus Crispus* was 76%, while that obtained with non-overwintered-stressed *Chondrus crispus* was 33.3% ($P < 0.01$). Results of SF-36 general health status after the treatment demonstrated that 37 patients (74%) and 11 patients (36.7%) felt better than before in the overwintered-stressed *Chondrus Crispus* group and non-overwintered-stressed *Chondrus crispus* group, respectively ($P < 0.01$). A great improvement of subjective exhaustion, fatigue, pain, digestive, and peristalsis disturbances symptoms, in addition to mood and concentration amelioration that would be a consequence of symptomatology regression, was also observed. **Conclusions:** This retrospective observational comparative study evidences that overwintered-stressed *Chondrus Crispus* improved musculoskeletal and articular symptomatology related diseases better than non-overwintered-stressed *Chondrus crispus*.

Key words: *Chondrus crispus*; Energy; fatigue; Musculoskeletal symptoms; Articular symptoms; Overwintered; Cold; L-citrullin-L-arginine

INTRODUCTION

The red seaweed *Chondrus crispus* (Rhodophyta) is widely distributed in the northern Atlantic.¹ As an economically important seaweed species in the Atlantic Canada

region, *Chondrus crispus* is also cultivated on land in Nova Scotia, Canada.¹

In addition to high content of total proteins, oligopeptides and pigments, this alga is rich in the water-soluble

Access this article online

Website:

<http://nepjol.info/index.php/AJMS>

DOI: 10.3126/ajms.v9i6.20978

E-ISSN: 2091-0576

P-ISSN: 2467-9100

Address for correspondence:

Carmen Laurino, Department of General Surgery and Surgical Specialities, University of Modena and Reggio Emilia. Largo del Pozzo 71, 41124 Modena (MO). Second Opinion Medical Network, Modena (MO), Italy. **Phone:** +390594222483. **E-mail:** carmen.laurino@hotmail.it

© Copyright AJMS

polysaccharide carrageenan (approximately 50–65 % on a basis of dry weight).^{2,3} Carrageenan is widely used in the food industry as a thickener, stabilizer and emulsifier.

Thanks to the high content of total proteins among these seaweeds, *Chondrus crispus* is in the folk medicine, reputed as effective supplement for some symptoms such as fatigue, asthenia, and weakness and for supporting skeletal muscles in sports athletes.⁴

Physiologically, the food content in amino acids is the substrate of biosynthesis of structural and functional proteins in the body. These digested amino acids can be used for oxidative phosphorylation and gluconeogenesis^{5,6} as well as the facilitation of numerous physiological functions including acting as precursors for the biosynthesis of neurotransmitters, hormones, phosphoglycerols, glycolipids and nucleic acids.^{7,8}

It has been estimated that the skeletal muscles in the human body are 40–60% of body mass and thus represent the major bulk of the body's protein.⁹ The body does not have specific protein stores, but when it is not possible to obtain sufficient protein via ingestion during exercise, illness or trauma, it breaks down proteins to amino acids via the process of proteolysis where the non-myofibrillar proteins display a high turnover rate to meet demands.¹⁰ The amino acids released from this turnover of protein can enter the blood circulation for metabolism as required and can be lost in sweat and urine.^{5,6}

An increased amino acids recruitment would be seen during illness and recovery from trauma¹¹ as also in sarcopenia¹² as in patients with critical illness or other muscle wasting illness.¹³ Increased losses of amino acids were observed in cancer patients affected by fatigue during and following radiation therapy and chemotherapy, involving amino acid homeostasis.¹¹ Significantly, depleted amino acid levels have also been associated with long-term fatigue leading often to a frank nitrogen imbalance.¹⁴

This retrospective observational comparative study investigates and compares the clinical effects of overwintered-stressed *Chondrus Crispus** and non-overwintered-stressed *Chondrus crispus* dietary supplementations for the treatment of musculoskeletal and articular symptomatology related diseases.

MATERIALS AND METHODS

Patients. We reviewed medical records (electronic or paper-based) of 80 patients that had appealed to our “Second Opinion Medical Network”, (Modena, Italy), between January and April 2018, because of musculoskeletal and

articular symptomatology (asthenia, fatigue, articular, musculoskeletal, rheumatic and post-traumatic pain, digestive and peristalsis disturbances and migraine). Patients were aged over 40 years and were affected at least 6 months by different clinical conditions (cancer, infections, sarcopenia, colitis, rheumatologic, traumatic, musculoskeletal, articular, autoimmune and genetic diseases) with an attested related symptomatology and diagnosis. The Second Opinion Medical Network is a consultation referral web and Medical Office System recruiting a wide panel of real-time available specialists, to whom any patient affected by any disease or syndrome and not satisfied with the diagnosis or therapy, can apply for an individual clinical audit.¹⁵ Due to the doctor-patient communication gap, most of the patients usually wander around the medical websites looking for proper answers to their health problems. However, this search often becomes compulsive and obsessive and is frequently ambiguous and frustrating. Palmieri *et al.*,¹⁶ describe this borderline or even pathological behaviour as the “Web Babel Syndrome” – a psychological imbalance affecting young and elderly patients, especially those with multiple synchronous diseases who receive from their caregivers heterogeneous and misleading information or advice, including confused, contradictory statements and prescriptions.¹⁷ To deal with this problem, the Second Opinion Network aims to be a useful “problem-solving” support revisiting each diagnostic and therapeutic step and properly re-addressing tailored treatments and prognoses, as well as preventing unnecessary investigational procedures and unhelpful and expensive medical and surgical interventions.¹⁵

All patients used pharmacological treatments, dietary supplementation, surgery, manual and electro - medical physiotherapy especially for the management of pain and strain with only partial benefit from them. However, these strategies produce light, moderate or severe side effects (e.g., hypersensitivity reactions, sensation of pressure or constriction, flushing to face and in the thoracic region, asthenia, myalgia, drowsiness, insomnia, restlessness, vertigo, gastrointestinal symptoms, skin rashes, nausea, vomiting, etc.), and frequent drug interactions and contraindications. Dietary supplementation included herbal products and nutraceutical supplementations, while electro-medical physiotherapy was based on laser therapy, iontophoresis, magneto therapy, electrostimulation, etc.

In our clinical practice, we washed out previous treatments for a period of 2 weeks, and then the dietary supplementations were administered.

The selected patients were informed, via individual interview, and informed consent previously approved by the Local Institutional Review Board under the Helsinki Declaration.

Study design and dietary supplementations. We run a retrospective observational “*not inferiority*” study for 3 weeks duration. At the start up the patients were prescribed 3 capsules/day after the main meals of overwintered-stressed Chondrus Crispus of either non-overwintered stressed *Chondrus crispus* dietary supplementations. Each capsule contains 500 mg of 100% powder of the overwintered-stressed red seaweed or 500 mg of 100% powder of the non-overwintered-stressed red seaweed. overwintered-stressed *Chondrus Crispus* is naturally enriched in a dipeptide, the L-citrullinyl-L-arginine (2.8% - 4%), with antioxidant and energizing properties, compared to the non-overwintered-stressed *Chondrus crispus* (0.2%). The cultivation method of overwintered-stressed *Chondrus Crispus* consists to expose to overwintered conditions the *Chondrus crispus* with increased production of amino acids and others peptides (European Patent 1652435B1). Energizing and antioxidant peptides contained in both the dietary supplementations are summarized in Table 1.

The first clinical examination consisted in the evaluation of the physical status of the patient. Tolerability and adverse effects were assessed weekly during the treatment period through direct contact (email or telephone) with the patients or their parents.

Quality of life (QOL) assessment was performed using the Short Form-36 (SF-36) health survey questionnaire before starting the treatment and after the fourth week. The questionnaire measures (A) symptomatology; (B) health status before starting the treatment defined as (i) excellent; (ii) good; (iii) liable; (iv) shoddy; (C) general health status after the treatment defined as (i) better than before; (ii) more or less the same as before; (iii) worse than before. The percentage scores range from 0% (lowest or worst response) to 100% (highest or best possible response)¹⁸. Benefits declared by patients were also reported after the treatment in addition to some subjective observations related to the symptomatology and to the health status. Adverse reactions presented during the treatment were also declared.

Statistical analysis. The statistical analysis was performed using the Mann-Whitney test (continuous variables not normally distributed) and the chi-squared test (categorical variables). Statistical significance was set at a P value < 0.05, and all data were analysed using the R software, version 3.1.2.

RESULTS

Patients. Fifty patients [28 women (56%) and 22 men (44%), aged between 40 and 85 years old (mean age 64 years old)] were treated with overwintered-stressed *Chondrus Crispus* dietary supplementation and 30 patients [15 women (50%) and 15 men (50%), aged between 40 and 83 years old (mean

age 65 years old)] were treated with the non-overwintered-stressed *Chondrus crispus* dietary supplementation formula.

- (A) Results of SF-36 symptomatology of both the treated group are summarized in Table 2.
- (B) Results of SF-36 health status before starting the treatment with overwintered-stressed *Chondrus Crispus* demonstrated that 38 patients (76%) had a liable health and 12 patients (24%) had a shoddy health. Results of SF-36 health status before starting the treatment of the non-overwintered-stressed *Chondrus crispus* group demonstrated that 21 patients (70%) had a liable health and 9 patients (30%) had a shoddy health. Anyone declared to have excellent or good health.
- (C) Results of SF-36 general health status after the treatment with overwintered-stressed *Chondrus Crispus* demonstrated that 37 patients (74%) felt better than before and 31 patients (26%) felt unchanged. Results of SF-36 general health status after the treatment of the non-overwintered-stressed *Chondrus crispus* group demonstrated that 11 patients (36.7%) felt better than before and 19 patients (63.3%) felt more or less the same as before. Anyone declared to felt a worse health than before ($P < 0.01$).

Thirty eight patients (76%) treated with overwintered-stressed *Chondrus Crispus* declared to have benefits to the treatment and 12 patients (24%) did not report any relief. Of the non-overwintered-stressed *Chondrus crispus* group, 10 patients (33.3%) declared to have benefits to the treatment and 20 patients (66.7%) did not report any relief ($P < 0.01$).

Subjective observations related to the symptomatology declared by patients after the treatment are summarized in Table 3.

Subjective observations about health status declared by patients after the treatment are summarized in Table 4.

Five patients (10%) treated with overwintered-stressed *Chondrus Crispus* referred adverse reactions to the treatment (3 patients had diarrhoea and 2 patients had constipation), so the dosage was reduced to 2 capsules/day. The treatment was well tolerated at the dosage of 3 capsules/day in 90% of patients. Of the non-overwintered-stressed *Chondrus crispus* group, any patients referred adverse reactions to the treatment that was well tolerated at the dosage of 3 capsules/day in 100% of patients. Any other adverse reaction was observed in both the groups.

Muscle energy recovery of subjects treated with overwintered-stressed *Chondrus Crispus* was higher (84%, 42/50 patients; Table 4) than in the group treated with non-overwintered-stressed *Chondrus crispus* (33.3%, 10/30 patients; Table 4), as shown the request of the

Table 1: Comparative table of non-overwintered-stressed *chondrus crispus* and overwintered-stressed *chondrus crispus* dietary supplementations nutritional values. Note that nutritional values of overwintered-stressed *chondrus crispus* are referred to different cultivations in the related years after overwintered exposition

Parameter	Unit	Non-overwintered-stressed <i>chondrus crispus</i>	Overwintered-stressed <i>chondrus crispus</i> (2014)	Overwintered-stressed <i>chondrus crispus</i> (2015)	Overwintered-stressed <i>chondrus crispus</i> (2017)
Citrulline	g/kg	2.81	5.16	4.69	3.33
Tryptophan	g/100	0.174	0.203	0.195	0.196
Hydroxyproline	g/100	< 0.05	< 0.05	< 0.05	< 0.05
Ornithine	g/100	0.178	0.889	0.532	0.526
Threonine	g/100	0.684	0.802	0.706	0.744
Aspartic acid	g/100	1.47	1.81	1.52	1.63
Serine	g/100	0.802	0.908	0.756	0.814
Lysine	g/100	0.787	1.05	0.882	0.896
Valine	g/100	0.795	0.996	0.872	0.881
Proline	g/100	0.669	1.2	0.961	1.00
Alanine	g/100	0.957	1.15	1.02	1.07
Phenylalanine	g/100	0.658	0.877	0.813	0.820
Isoleucine	g/100	0.652	0.778	0.692	0.696
Glycine	g/100	0.789	0.99	0.845	0.900
Thirosine	g/100	0.466	0.561	0.475	0.564
Arginine	g/100	1.02	3.83	2.48	2.52
Leucine	g/100	1.05	1.27	1.12	1.20
Histidine	g/100	0.200	0.263	0.234	0.253
Glutamic acid	g/100	1.85	3.06	2.21	2.24
Methionine	g/100	0.290	0.342	0.321	0.324
Cysteine	g/100	0.249	0.341	0.271	0.274
Taurine	mg/100	333	319	452	468
L-citrullin-L-arginine	g/100	0.2	4.1	2.8	3.0
Azote	g/100	2.96	5.27	3.81	3.92
Proteins	g/100	18.5	32.9	23.8	24.5
Sugars	g/100	2.9	< 0.1	< 0.1	< 0.1
Fats	g/100	0.6	0.6	1.0	1.2
Minerals	g/100	25.47	21.91	24.07	23.58
Sodium	g/100	4.4	3.3	4.1	3.982

Table 2: Symptomatology declared by patients before starting the treatment assessed by the SF-36 questionnaire. Results are expressed in terms of symptoms' frequency

Symptoms	Frequency	
	Overwintered-stressed <i>chondrus crispus</i> group (N=50)	Non-overwintered-stressed <i>chondrus crispus</i> group (N=30)
Asthenia	25	16
Fatigue	19	6
Articular pain	5	5
Musculoskeletal pain	8	4
Post-traumatic pain	1	1
Rheumatic pain	6	2
digestive and peristalsis disturbances	8	0
Migraine	5	3

same patients to follow-up with the dietary supplement administration at the end of the first bottle due to the observed and subjective clinical benefits, while patients treated with non-overwintered-stressed *Chondrus crispus* did not require to repeat the treatment.

The best treatment responders were people complaining of musculoskeletal and articular pain, due to articular and cartilaginous causes (with arthrosis, arthritis, lumbar pain

on a slipped disc basis). They declared satisfactory fitness recovery and joint mobility at the end of the treatment.

The energetic benefit was also observed in patients with cancer undergoing chemotherapy and radiotherapy with overwintered-stressed *Chondrus Crispus* dietary supplementation.

A further benefit observed in at least 30% of patients taking overwintered-stressed *Chondrus Crispus* said they

Table 3: Subjective observations related to the symptomatology declared by patients after the treatment. Results are expressed in terms of frequency

Subjective observations about symptoms	Frequency	
	Overwintered-stressed <i>chondrus crispus</i> group (N=50)	Non-overwintered-stressed <i>chondrus crispus</i> group (N=30)
Less exhaustion	19	5
Less fatigue	17	6
Mood improvement	13	1
Less pain	5	0
Mild improvement of the symptoms	5	3
Concentration improvement	2	0
Digestive and peristalsis disturbances improvement	3	0
No effects	9	21

Table 4: Subjective observations related to the health status declared by patients after the treatment. Results are expressed in terms of frequency

Subjective observations about health status	Frequency	
	Overwintered-stressed <i>chondrus crispus</i> (N=50)	Non-overwintered-stressed <i>chondrus crispus</i> group (N=30)
More strength and energy	42	10
Persistent asthenia and/or fatigue	10	15
Symptoms persistence but the patients felt better before starting the treatment	10	4
Improvement of serenity	10	1
Absence of symptoms	3	1

had benefits on the normalization of intestinal peristalsis and on digestive functions (patients suffering from colitis, 3/8 patients (Table 3-4).

In conclusion, as assessed before, the general benefit improvement of overwintered-stressed *Chondrus Crispus* administration was 76%, while that obtained with non-overwintered-stressed *Chondrus crispus* was 33.3% (P <0.01)

DISCUSSION

This retrospective observational “not inferiority” study evidences that overwintered-stressed *Chondrus Crispus* dietary supplementation improved musculoskeletal and articular symptoms with underlying inflammatory and degenerative background better than non-overwintered-stressed *Chondrus crispus*, with very mild side effects. Specifically, it has been observed a great improvement of exhaustion, fatigue, pain, digestive, and peristalsis disturbances symptoms, in addition to mood and mental concentration amelioration probably as surrogate endpoints of symptoms. Comparatively, the general benefit of treatment with the overwintered-stressed red seaweed was 76%, while with the one non-overwintered-stressed was 33.3% (P <0.01).

A possible explanation of this different performance is that overwintered exposition of *Chondrus crispus* naturally enriched the seaweed in a dipeptide, the L- citrullinyl-L-arginine, compared to other sources of regular *Chondrus*

crispus (Table 1). In addition, this one has a major content in total proteins that makes the dietary supplementation more energizing than the normal seaweed demonstrating the best therapeutic results obtained in patients treated with the overwintered-stressed *Chondrus crispus*. Seasonal variations in nutritional values of *Chondrus crispus* are notable, as described in Table 1. Furthermore, previous studies demonstrated seasonal different concentrations in amino acids and in the dipeptide L- citrullinyl-L-arginine in *Chondrus crispus* and in others red seaweeds.¹⁹ This one has been demonstrated to have *in vitro* antioxidant activity¹⁹. Laycock et al. (1980) demonstrated that cold exposure (8°) of *Chondrus crispus* improved this dipeptide production and it accumulates at this temperature.²⁰ This could be due to a direct effect of temperature on the enzyme systems involved in dipeptide metabolism or simply by a result of slower growth.²⁰ In fact, the experiments demonstrated that when *Chondrus crispus* was kept in nitrogen deficient culture at higher temperatures (15°), L- citrullinyl-L-arginine was consumed rapidly, by arginase enzyme that catalyse the hydrolysis of the dipeptide bond between citrulline and arginine. This condition is not verified at lower temperature. In fact, it would be advantageous for the plant to invest the energy needed for uptake and reduction of nitrate and the biosynthesis of nitrogen storage compounds during a time of low temperatures when growth is restricted and there is a surplus of available nitrate.²⁰ Generally speaking, dipeptides, has a high nutritional values in terms of energetic contribution because of the break of chemical

bonds between the two amino acids, releases a stronger energetic power compared to single amino acid content. In fact, commercially available dietary supplementation with the claim to improve strength and energy has a high content of others dipeptide, such as L-carnosine (β -alanyl-L-histidine) to achieve the fine sporting art results due to the buffering activities of carnosine and its related imidazole-containing compounds which contribute to the maintenance of the acid-base balance in the acting muscles.²¹

A recent study demonstrated that a further red seaweed that coexisted with *Chondrus crispus*, e.g., *Mostocarpus stellatus*, has a greater freezing tolerance when compared with *Chondrus crispus* due to its definite proline content storage after cold exposure.²² In this study, a range of molecular mechanism have been proposed for cryoprotectants, including detoxifying radical oxygen species (ROS), scavenger with the function of compatible osmolytes, and replacing water in the stabilization of membrane and protein conformation.²² With regard to membrane integrity, cryoprotectants such as proline interact with membrane surfaces to limit damaging phospholipid phase changes or membrane fusion during freezing-induced cell collapse.^{23,24}

Clinical conditions with significantly depleted amino acid levels have, such as cancer, infections, sarcopenia, colitis, rheumatologic, trauma, musculoskeletal, articular, autoimmune and genetic diseases have been associated with long-term fatigue due to negative nitrogen balance in the energetic metabolism.¹⁴ This can be due to inadequate amino acids availability because of insufficient protein intake or impaired digestion. The amino acids requirement is balanced by proteolysis of non-myofibrillar muscle proteins. A prolonged state of negative nitrogen balance could result in further proteolysis of myofibrillar proteins, with subsequent muscle wasting and damage. Increased metabolic activities to support exercise, mount host defences against infection, or support recovery from illness and injury, place additional demands on protein turnover within the body.^{9,10,25} If a net negative nitrogen balance is associated with fatigue then it would follow that amino acid supplementation would have the potential to assist in restoring nitrogen balance.²⁶

The benefits of overwintered-stressed *Chondrus Crispus* might also depends on the higher total proteins concentrations compared to the non-stressed red seaweed (from 23.8 g/100 to 32.9 g/100 and 18.5 g/100 respectively and amino acids content as especially arginine and citrulline (Table 1).

In conclusion, overwintered-stressed *Chondrus Crispus* supplementation displayed most energizing properties

than the non-stressed red seaweed dietary supplementation because of a huge content in amino acids and total proteins supplying deficiency.

* BIO-ARCT® (Iontec, Monaco)

Conflict of interest statement

The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

The authors hereby certify that all work contained in this article is original. The authors claim full responsibility for the contents of the article. The article has been neither published elsewhere nor submitted for publication simultaneously. If accepted, the paper will not be published elsewhere in the same or similar form, in English or in any other language

All the authors contributed equally to this work.

REFERENCES

- Liu J, Hafting J, Critchley AT, Banskota AH and Prithiviraj B. Components of the cultivated red seaweed *Chondrus crispus* enhance the immune response of *Caenorhabditis elegans* to *Pseudomonas aeruginosa* through the pmk-1, daf-2/daf-16, and skn-1 pathways. *Appl Environ Microbiol* 2013; 79(23):7343-7450.
- Chopin T GT and Davison I. Phosphorus and nitrogen nutrition in *Chondrus crispus* (Rhodophyta): effects on total phosphorus and nitrogen content, carrageenan production, and photosynthetic pigments and metabolism. *J Phycol* 1995; 31:10.
- McCandless EL, Craigie JS and Walter JA. Carrageenans in the gametophytic and sporophytic stages of *Chondrus crispus*. *Planta* 1973; 112(3):201-212.
- Braakhuis AJ and Hopkins WG. Impact of Dietary Antioxidants on Sport Performance: A Review. *Sports Med* 2015; 45(7):939-955.
- Boirie Y. Physiopathological mechanism of sarcopenia. *J Nutr Health Aging* 2009; 13(8):717-723.
- Jagoe RT and Engelen MP. Muscle wasting and changes in muscle protein metabolism in chronic obstructive pulmonary disease. *Eur Respir J Suppl* 2003; 46:52s-63s.
- Udenfriend S and Wyngaarden JB. Precursors of adrenal epinephrine and norepinephrine in vivo. *Biochim Biophys Acta* 1956; 20(1):48-52.
- de Koning TJ, Snell K, Duran M, Berger R, Poll-The BT and Surtees R. L-serine in disease and development. *Biochem J* 2003; 371(Pt 3):653-661.
- Poortmans JR, Carpentier A, Pereira-Lancha LO and Lancha A. Protein turnover, amino acid requirements and recommendations for athletes and active populations. *Braz J Med Biol Res* 2012; 45(10):875-890.
- Phillips SM. Protein requirements and supplementation in strength sports. *Nutrition* 2004; 20(7-8):689-695.
- Dunstan RH, Sparkes DL, Dascombe BJ, Macdonald MM, Evans CA and Stevens CJ. Sweat Facilitated Amino Acid Losses in Male Athletes during Exercise at 32-34 degrees C. *PLoS One* 2016; 11(12):e0167844.
- Martone AM, Lattanzio F, Abbatecola AM, Carpia DL, Tosato M

- and Marzetti E. Treating sarcopenia in older and oldest old. *Curr Pharm Des* 2015; 21(13):1715-1722.
13. Wandrag L, Brett SJ, Frost G and Hickson M. Impact of supplementation with amino acids or their metabolites on muscle wasting in patients with critical illness or other muscle wasting illness: a systematic review. *J Hum Nutr Diet* 2015; 28(4):313-330.
 14. Niblett SH, King KE, Dunstan RH, Clifton-Bligh P, Hoskin LA and Roberts TK. Hematologic and urinary excretion anomalies in patients with chronic fatigue syndrome. *Exp Biol Med* (Maywood) 2007; 232(8):1041-1049.
 15. Di Cerbo A and Palmieri B. The economic impact of second opinion in pathology. *Saudi Med J* 2012; 33(10):1051-1052.
 16. Palmieri B and Iannitti T. The Web Babel syndrome. *Patient Educ Couns* 2011; 85(2):331-333.
 17. Palmieri B, Iannitti T, Capone S, Fistetto G and Arisi E. Second opinion clinic: is the Web Babel Syndrome treatable?. *Clin Ter* 2011; 162(6):575-583.
 18. McHorney CA, Ware JE, Lu JF and Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. *Med Care* 1994; 32(1):40-66.
 19. Laycock MV, Morgan KC and Craige JS. Physiological factors affecting the accumulation of L-citrullinyl-L-arginine in *Chondrus crispus*. *Can J Bot* 1980; 59:6.
 20. Laycock MV and Craige JS. The occurrence and seasonal variation of gigartinine and L-citrullinyl-L-arginine in *Chondrus crispus* Stackh. *Can J Biochem* 1977; 55(1):27-30.
 21. Babizhayev MA and Yegorov YE. An "enigmatic" L-carnosine (beta-alanyl-L-histidine)? Cell proliferative activity as a fundamental property of a natural dipeptide inherent to traditional antioxidant, anti-aging biological activities: balancing and a hormonally correct agent, novel patented oral therapy dosage formulation for mobility, skeletal muscle power and functional performance, hypothalamic-pituitary- brain relationship in health, aging and stress studies. *Recent Pat Drug Deliv Formul* 2015; 9(1):1-64.
 22. McCarty AT and Sotka EE. Geographic variation in feeding preference of a generalist herbivore: the importance of seaweed chemical defenses. *Oecologia* 2013; 172(4):1071-1083.
 23. Takahashi D, Li B, Nakayama T, Kawamura Y and Uemura M. Plant plasma membrane proteomics for improving cold tolerance. *Front Plant Sci* 2013; 4:90.
 24. Anchoadoguy TJ, Rudolph AS, Carpenter JF and Crowe JH: Modes of interaction of cryoprotectants with membrane phospholipids during freezing. *Cryobiology* 1987; 24(4):324-331.
 25. Waterlow JC and Jackson AA. Nutrition and protein turnover in man. *Br Med Bull* 1981; 37(1):5-10.
 26. Dunstan RH, Sparkes DL, Macdonald MM, De Jonge XJ, Dascombe BJ and Gottfries J. Diverse characteristics of the urinary excretion of amino acids in humans and the use of amino acid supplementation to reduce fatigue and sub-health in adults. *Nutr J* 2017; 16(1):19.

Authors Contribution:

BP- Concept and design of the study, reviewed the literature, manuscript preparation and critical revision of the manuscript; **CL**- Concept, collected data and review of literature and helped in preparing first draft of manuscript, critical revision of the manuscript; **MV**- Concept of study, collected data and review of study.

Work attributed to:

Department of General Surgery and Surgical Specialities, University of Modena and Reggio Emilia, Second Opinion Medical Network, Modena (MO), Italy.

Orcid ID:

Prof. Beniamino Palmieri- <http://orcid.org/0000-0002-0871-138X>

Dr Maria Vadalà- <http://orcid.org/0000-0001-7873-5072>

Dr Carmen Laurino- <http://orcid.org/0000-0002-3020-2338>

Source of Support: Not Applicable., **Acknowledgement:** None., **Conflict of Interest:** None declared.